Abstracts tagged "Clinical research"

Abstract Number: 1309 • 2015 ACR/ARHP Annual Meeting
Defining an Acceptable Level of MRI Inflammation in Rheumatoid Arthritis
Joshua Baker¹, Mikkel Østergaard², Daniel Baker³, Paul Emery⁴ and Philip G. Conaghan⁵, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ³Immunology, Centocor Inc., Malvern, PA, ⁴Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁵University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom
Background/Purpose: Imaging-detected inflammation persists in many rheumatoid arthritis (RA) patients despite therapy. We used data from two clinical trials of golimumab to determine thresholds for…
Abstract Number: 1661 • 2015 ACR/ARHP Annual Meeting
Translational Data and Phase 1 Study Results of a New Monoclonal Antibody Targeting Toll like Receptor 4 (TLR4) Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine
Emmanuel Monnet¹, Limin Shang¹, Geneviève Lapeyre¹, Kathy De Graaf², Eric Hatterer¹, Gaelle Wambiekele¹, Walter Ferlin¹, Philippe Jacqmin³, Cem Gabay⁴, Jeremy Sokolove⁵, Simon Jones⁶, Ernest H. Choy⁷, Iain B. McInnes⁸, Marie Kosco-Vilbois¹ and Cristina De Min¹, ¹NovImmune S.A., Geneva, Switzerland, ²Novimmune S.A., Geneva, Switzerland, ³SGS Exprimo, Mechelen, Belgium, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁶Cardiff Institute of Infection & Immunity, Cardiff, United Kingdom, ⁷Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁸Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Innate immunity is implicated in RA pathogenesis and is likely mediated via TLR pathways, with anti-citrullinated protein antibodies (ACPA) serving as key triggers. NI-0101…
Abstract Number: 1664 • 2015 ACR/ARHP Annual Meeting
Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.
Jose L. Pablos¹, Navarro Sarabia F², Francisco J. Blanco³, Jose Andres Roman Ivorra⁴, Alberto Alonso⁵, Emilio Martin-Mola⁶ and Miguel Cantalejo-Moreira⁷, ¹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ²Rheumatologist Service, Hospital. Virgen Macarena, Sevilla, Spain, ³Cartilage Biology Group. Rheumatology Division, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁴Rheumatology, H.U. P. La Fe, Valencia, Spain, ⁵H Cruces, Baracaldo, Spain, ⁶H La Paz, Madrid, Spain, ⁷Rheumatology Unit, Hospital de Fuenlabrada, Fuenlabrada, Spain
Background/Purpose: Tocilizumab (TCZ) represents an efficacious alternative for patients with rheumatoid arthritis (RA) with an inadequate clinical response to biological or non-biological disease-modifying anrirheumatic drugs…
Abstract Number: 2111 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Alexandra Steinberg¹, Harinder Chera¹, Yun-Jung Choi¹, Robert Martin¹, Charles McWherter¹, Yunbin Zhang², Pol Boudes¹ and on behalf of the Arhalofenate Anti-Flare Therapy Study Group, ¹Cymabay Therapeutics, Newark, CA, ²INC Research, Raleigh, NC
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) to treat gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular UA transporter, and…
Abstract Number: 2302 • 2015 ACR/ARHP Annual Meeting
The Impact of Prior Fibromyalgia Treatment on the Response to Pregabalin in Fibromyalgia Clinical Trials
Lynne Pauer¹, Andrew Clair², Pritha Bhadra Brown², Marie Ortiz² and Joseph Scavone¹, ¹Pfizer Inc, Groton, CT, ²Pfizer Inc., New York, NY
Background/Purpose: Fibromyalgia (FM) is a chronic, widespread pain disorder for which Lyrica is an approved treatment. Antidepressants, gabapentin, muscle relaxants, and opioids are frequently used…
Abstract Number: 2440 • 2015 ACR/ARHP Annual Meeting
Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis
Jaime Guzman¹, Andrew Henrey², Thomas Loughin², Roberta Berard³, Natalie Shiff⁴, Roman Jurencak⁵, Susanne Benseler⁶, Lori B. Tucker⁷ and ReACCh-Out Investigators, ¹Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ²Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada, ³Children's Hospital of Western Ontario, London, ON, Canada, ⁴Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶Alberta Children's Hospital Research Institute/University of Calgary, Calgary, AB, Canada, ⁷Rheumatology, BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: To define distinct disease course groups among children with Juvenile Idiopathic Arthritis (JIA) based on observed changes in quality of life, pain, medication requirements,…
Abstract Number: 2754 • 2015 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of BI 655064, an Antagonistic Anti-CD40 Antibody Following Single-Dose Administration in Chinese and Japanese Healthy Volunteers
Jiyoon Kim¹, Yasuhiro Tsuda², Kazuhiko Yamamoto³, Ralf Thiedmann⁴, Corinna Schoelch⁴, Stephen Norris⁵, Steven Padula⁶, Juergen Steffgen⁴ and In-Jin Jang⁷, ¹Boehringer Ingelheim Korea Ltd., Seoul, South Korea, ²Clinical PK/PD department, Nippon Boehringer-Ingelheim.Co.,Ltd., Kobe, Japan, ³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁵Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany, ⁷Seoul National University Hospital, Seoul, South Korea
Background/Purpose: The CD40-CD40L pathway may play a major role in autoimmune disorders like rheumatoid arthritis or SLE. Blocking this pathway may be a promising new…
Abstract Number: 3145 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Modified-Release Prednisone in Patients with Polymyalgia Rheumatica: Results of a Multicenter, Randomized, Active-Controlled Phase 3 Study
Maurizio Cutolo¹, Michael Hopp², Stefan Liebscher², Bhaskar Dasgupta³ and Frank Buttgereit⁴, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²Medical Science, Mundipharma Research GmbH & Co. KG, Limburg, Germany, ³Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁴Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Polymyalgia rheumatica (PMR) is characterized by persisting proximal pain and morning stiffness of the neck, shoulder and hip girdles of 2 weeks' duration, an…
Abstract Number: 314 • 2015 ACR/ARHP Annual Meeting
A Double-Blind, Randomized, Controlled, Four Parallel Arm, Dose-Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Intra-Articular (IA) Injections of Fasitibant in Patients with Symptomatic OA of the Knee
Claudia Gabriele Werner¹, Karel Pavelka², Andrea Nizzardo³, Cristina Rossi³, Simona Scartoni³, Maria Paola Contini³, Serena di Molfetta³, Monica Bertolotti³, Angela Capriati³ and Carlo Alberto Maggi⁴, ¹Clinical Research, A. Menarini Research & Business Service GmbH, Berlin, Germany, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Clinical Research Department, Menarini Ricerche S.p.A., Florence, Italy, ⁴Menarini Ricerche S.p.A., Florence, Italy
Background/Purpose: Fasitibant (FAS) is a competitive, potent and selective antagonist of the bradykinin B2 receptor administered IA for SOAK. In response to positive outcomes in…
Abstract Number: 2230 • 2014 ACR/ARHP Annual Meeting
Treatment of Symptomatic Knee Osteoarthritis with Oral Salmon Calcitonin: Results from Two Phase 3 Randomized Clinical Trials
Morten Asser Karsdal¹, Anne C. Bay-Jensen², Asger Bihlet³, Peter Alexandersen⁴, Inger Byrjalsen³, Jeppe Andersen³, Bente J. Riis³ and Claus Christiansen³, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Center for Clinical and Basic Research, Vejle, Denmark
Background/Purpose: To evaluate the structure-modifying and symptom efficacy, as well as safety and tolerability of oral salmon calcitonin (sCT) formulated with a 5-CNAC carrier (a…
Abstract Number: 1553 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Philip J. Mease¹, Roy Fleischmann², Owen Davies³, Tommi Nurminen⁴ and Désirée van der Heijde⁵, ¹Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Early non-response to biologic therapy has been shown to be associated with a low probability of long-term response in rheumatoid arthritis1 and psoriasis2. However,…
Abstract Number: 1505 • 2014 ACR/ARHP Annual Meeting
The Biosimilar Landscape: A Systematic Review of Its Current Status
Niti Goel^1,2 and Kamali Chance³, ¹Rheumatology Center of Excellence, Quintiles, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Global Biosimilars Unit, Quintiles, Durham, NC
Background/Purpose In the last 5 years, the number of biosimilars in development for the treatment of immunologic diseases has increased as innovator etanercept (ETA), infliximab (IFX), adalimumab…
Abstract Number: 1436 • 2014 ACR/ARHP Annual Meeting
Impact of Depression on Clinical and Social Outcomes in Patients with Rheumatoid Arthritis: Comparative Study in Germany and Brazil
Harriet Morf¹, Olga Malysheva², G da Rocha³, Anna Beatriz Vargas³ and Christoph G. Baerwald², ¹Department of Internal Medicine, University Hospital, Leipzig, Germany, ²Rheumatology, University Hospital, Leipzig, Germany, ³Ambulatório de reumatologia da Policlínica Piquet Carneiro, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose Rheumatoid Arthritis (RA) can be associated with psychological disorders and especially depression. About 13 – 20 % of patients have clinical significant depression. It…
Abstract Number: 1256 • 2014 ACR/ARHP Annual Meeting
Clinical and Temporal Characterization of Anti-Jo-1 Positive Anti-Synthetase Syndrome: Preliminary Results of an International Multicentre Study
Lorenzo Cavagna¹, Miguel A González-Gay², Santos Castañeda-Sanz³, Franco Franceschini⁴, Paolo Airo⁵, Ilaria Cavazzana⁶, Laura Nuno⁷, Trinitario Pina Murcia², Francisco Javier Lopez Longo⁸, Norberto Ortego-Centeno⁹, Rossella Neri¹⁰, Simone Barsotti¹⁰, Enrico Fusaro¹¹, Simone Parisi¹², Giuseppe Paolazzi¹³, Giovanni Barausse¹³, Luca Quartuccio¹⁴, Elena Bartoloni-Bocci¹⁵, Carlo Selmi¹⁶, Carlo Alberto Scirè¹⁷, Elena Bravi¹⁸, Javier Bachiller Corral¹⁹, Lesley Ann Saketkoo²⁰, Gianluigi Bajocchi²¹, Raffaele Pellerito²², Marcello Govoni²³, Andreas Schwarting²⁴, Christof Specker²⁵, Carlomaurizio Montecucco¹ and Roberto Caporali²⁶, ¹Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario de La Princesa. Madrid. Spain, Madrid, Spain, ⁴AO Spedali Civili, Rheumatology and Clinical Immunology Unit, Brescia, Italy, ⁵Rheumatology and Clinical Immunology, Spedali Civili, AO Spedali Civili, Brescia, Italy, ⁶Rheumatology and Clinical Immunology Unit, AO Spedali Civili, Brescia, Italy, ⁷Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁸Rheumatology, Hospital Gregorio Marañón. Madrid, Madrid, Spain, ⁹Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁰Rheumatology Unit, University of Pisa, Pisa, Italy, ¹¹Department of Rheumatology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ¹²Rheumatology, Azienda Ospedaliera Città Della Salute e della Scienza, Turin, Italy, ¹³Rheumatology, Santa Chiara Hospital, Trento, Italy, ¹⁴Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ¹⁵Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁶Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy, ¹⁷Italian Society for Rheumatology, Milan, Italy, ¹⁸Internal Medicine, Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy, ¹⁹Rheumatology, Hospital Ramon y Cajal, Madrid, Spain, ²⁰Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²¹Department of Internal Medicine, Rheumatology Unit, Arcispedale S Maria Nuova. IRCCS, Reggio Emilia, Italy, ²²Rheumatology, Ospedale Mauriziano, Turin, Italy, ²³Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Ferrara, Italy, ²⁴Rheumatology, University Hospital Johannes-Gutenberg, Mainz, Germany, ²⁵Rheumazentrum Rhein-Ruhr e.V., St. Josef Krankenhaus (Kliniken Essen Süd), Universitätsklinikum Essen, Esssen, Germany, ²⁶Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Background/Purpose: anti Jo-1 antibodies are the main marker of the antisynthetase syndrome (As), a connective tissue disease chiefly characterized by arthritis (A), myositis (M) and…
Abstract Number: 912 • 2014 ACR/ARHP Annual Meeting
A Consensus Hybrid Definition Using a Conjoint Analysis Is the Proposed As Response Criteria for Minimal and Moderate Improvement for Adult Polymyositis and Dermatomyositis Clincal Trials
Rohit Aggarwal¹, Lisa G. Rider², Nicolino Ruperto³, Nastaran Bayat², Brian Erman⁴, Brian M. Feldman⁵, Adam M. Huber⁶, Chester V. Oddis⁷, Ingrid E. Lundberg⁸, Anthony A. Amato, MD^9,10, Robert G. Cooper, MD, FRCP¹¹, Hector Chinoy¹², Maryam Dastmalchi¹³, David Fiorentino¹⁴, David Isenberg¹⁵, James D. Katz¹⁶, Andrew L. Mammen¹⁷, Marianne de Visser¹⁸, Steven R. Ytterberg¹⁹, Katalin Danko²⁰, Luca Villa²¹, Mariangela Rinaldi²¹, Howard Rockette²², Peter A. Lachenbruch², Frederick W. Miller² and Jiri Vencovsky, MD, DSc²³, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁰Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹¹MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ¹²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹³Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁴Dermatology, Stanford University, Redwood City, CA, ¹⁵Centre for Rheumatology Research, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ¹⁶NIAMS, NIH, Bethesda, MD, ¹⁷Neurology and Medicine, Johns Hopkins University, Baltimore, MD, ¹⁸Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands, ¹⁹Rheumatology Division, Mayo Clinic, Rochester, MN, ²⁰Institute of Rheumatology, University of Debrecen, Hungary, Debrecen, Hungary, ²¹Pediatria II, Reumatologia, PRINTO, IRCCS Istituto G. Gaslini, Genova, Italy, ²²University of Pittsburgh, Pittsburgh, PA, ²³Institute of Rheumatology, Charles University, Prague, Czech Republic
Background/Purpose: To develop consensus on definitions of improvement (DOIs) for minimal and moderate improvement (and draft preliminary criteria for major improvement) in adult dermatomyositis (DM)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.